|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trastuzum ab:mechanism of action, resistance and Future perspectives in Her-2 overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 2 | Lapatinib: a dual inhibitor of EGFR and HER-2 tyrosine kinase activ- ity 显示文摘 | Montemurro F Valabrega G Aglietta M | 2007 | Expert Opin Biol Ther2007，7，2： | 1 |
| 3 | HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 显示文摘 | Valabrega G Capellero S Cavalloni G | 2011 | Breast Cancer Res Treat2011，130，1： | 1 |
| 4 | Trastuzumab:mechanism of action,resistance and future perspectives in HER-2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 5 | Trastuzumab:mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，： | 1 |
| 6 | Trastuzum-ab: mechanism of action, resistance and future perspectives inHER2-overexpressing breast cancer 显示文摘 | VALABREGA G MONTEMURRO F AGUETTA M | 2007 | Ann Oncol2007，18，6： | 1 |
| 7 | Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 8 | Trastuzumab-based combination therapy for breast-cancer显示文摘 | Montemurro F Valabrega G Aglietta M | 2004 | Expert Opin Pharmatother2004，5，： | 1 |
| 9 | Trastuzumab:mechanism of action,resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 10 | Trastuzumab treatment in breast cancer显示文摘 | Montemurro F Valabrega G Aglietta M | 2006 | N Engl J Med2006，354，： | 1 |
| 11 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells 显示文摘 | Valabrega G Fagioli F Corso S | 2003 | Br J Cancer2003，88，3： | 1 |
| 12 | Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Arm Oncol2007，18，6： | 1 |
| 13 | Lapatinib-a dual inhibitor of EGFR and HER2 tyrosine kinase activity显示文摘 | Montemurro F Valabrega G Aglietta M | 2007 | Expert Opin Biol Ther2007，7，2： | 1 |
| 14 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells 显示文摘 | Valabrega G Fagioli F Corso S | 2003 | Br J Cancer2003，88，3： | 1 |
| 15 | Trastuzumab-based com-bination therapy for breast cancer显示文摘 | Montemurro F Valabrega G Aglietta M | 2004 | Expert Opin Pharmacoth-er2004，5，： | 1 |
| 16 | Trastuzumab: mecha nism of action, resistance and future perspectives in HER2-over expressing breast cancer显示文摘 | Valabrega G Aglietta M | 2007 | An nals of ()ncology2007，18，6： | 1 |
| 17 | Trastuzumab:mechanism of action,resistance and future perspectivesin HER2-overexpressing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oncol2007，18，6： | 1 |
| 18 | Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpress- ing breast cancer显示文摘 | Valabrega G Montemurro F Aglietta M | 2007 | Ann Oneol2007，18，6： | 1 |
| 19 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells 显示文摘 | Valabrega G Fagioli F Corsol S | 2003 | Br J Cancer2003，88，： | 1 |
| 20 | Form rings and regular sequence显示文摘 | VALABREGA P VALLA G | 1978 | Nagoya Math J1978，72，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员